Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 6,232,000 | 6,385,000 | 7,282,000 | 6,682,000 | 6,660,000 |
| Cost of Goods | 1,317,000 | 1,266,000 | 1,398,000 | 1,274,000 | 1,346,000 |
| Gross Profit | 4,915,000 | 5,119,000 | 5,884,000 | 5,408,000 | 5,314,000 |
| Operating Expenses | 3,715,000 | 3,722,000 | 3,920,000 | 3,252,000 | 3,446,000 |
| Operating Income | 1,200,000 | 1,397,000 | 1,964,000 | 2,156,000 | 1,868,000 |
| Interest Expense | 121,000 | 115,000 | 143,000 | 135,000 | 134,000 |
| Other Income | 7,000 | 22,000 | 15,000 | 9,000 | 11,000 |
| Pre-tax Income | 1,086,000 | 1,304,000 | 1,836,000 | 2,030,000 | 1,745,000 |
| Income Tax | 255,000 | 292,000 | 316,000 | 511,000 | 141,000 |
| Net Income Continuous | 831,000 | 1,012,000 | 1,520,000 | 1,519,000 | 1,604,000 |
| Minority Interests | 8,000 | 1,000 | 13,000 | 8,000 | 7,000 |
| Net Income | $823,000 | $1,011,000 | $1,507,000 | $1,511,000 | $1,597,000 |
| EPS Basic Total Ops | 0.66 | 0.81 | 1.21 | 1.21 | 1.26 |
| EPS Basic Continuous Ops | 0.66 | 0.81 | 1.22 | 1.22 | 1.27 |
| EPS Diluted Total Ops | 0.66 | 0.81 | 1.21 | 1.20 | 1.26 |
| EPS Diluted Continuous Ops | 0.66 | 0.81 | 1.22 | 1.21 | 1.26 |
| EBITDA(a) | $2,139,000 | $2,048,000 | $2,728,000 | $2,901,000 | $2,378,000 |